<DOC>
	<DOCNO>NCT00005032</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Bcl-2 antisense oligodeoxynucleotide G3139 may increase effectiveness chemotherapy drug make tumor cell sensitive drug . PURPOSE : Phase I/II trial study effectiveness bcl-2 antisense oligodeoxynucleotide G3139 paclitaxel treat patient recurrent small cell lung cancer .</brief_summary>
	<brief_title>Bcl-2 Antisense Oligodeoxynucleotide G3139 Paclitaxel Treating Patients With Recurrent Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : I. Assess toxicity feasibility paclitaxel administration continuous intravenous bcl-2 antisense oligodeoxynucleotide G3139 patient recurrent small cell lung cancer . II . Evaluate clinical response patient population treat regimen . III . Evaluate correlation bcl-2 expression patient efficacy therapy . OUTLINE : Patients stratify accord whether receive prior taxane therapy ( yes v ) . Patients receive bcl-2 antisense oligodeoxynucleotide G3139 IV continuously day 1-6 follow 2 week rest . Paclitaxel IV administer 3 hour day 6 course . Treatment continue minimum 2 course absence disease progression unacceptable toxicity . Intrapatient dose escalation allow . Patients follow death . PROJECTED ACCRUAL : A total 19-33 patient accrue study within 12-18 month .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm small cell lung cancer Prior therapy include either cisplatin carboplatin progression either therapy within 3 month complete therapy Bidimensionally measurable disease CT scan xray , limit CNS No active CNS disease CNS metastasis allow measurable disease outside CNS complete course CNS radiotherapy clinically indicate recovered PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 OR Zubrod 02 Life expectancy : Not specify Hematopoietic : WBC least 3,000/mm3 Hemoglobin least 9 g/dL Platelet count least 100,000/mm3 Hepatic : Bilirubin great 1.5 mg/dL ALT/AST great 2 time upper limit normal ( ULN ) Alkaline phosphatase great 2 time ULN Renal : Creatinine great 1.5 mg/dL OR Creatinine clearance least 50 mL/min Cardiovascular : No evidence heart block great first degree , bundle branch block , ventricular supraventricular arrhythmia EKG No clinical evidence congestive heart failure , angina , document myocardial infarction within past 6 month Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No known hypersensitivity Cremaphor EL No significant concurrent medical psychiatric condition might place patient increase risk study PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics Endocrine therapy : Not specify Radiotherapy : See Disease Characteristics At least 4 week since prior radiotherapy site measurable disease great 20 % bone marrow Surgery : Not specify Other : No concurrent experimental drug cancer therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>recurrent small cell lung cancer</keyword>
</DOC>